Sylvester Comprehensive Cancer Center

Jonathan Trent, M.D., Ph.D.

Jonathan Trent, M.D., Ph.D.

Professor of Medicine

Description of Research

Dr. Trent earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center, and a fellowship in medical oncology at The University of Texas M. D. Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller School of Medicine, he held appointments as faculty of the University of Texas Graduate School of Biomedical Sciences at Houston, and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma and patient-oriented research. The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumor (GIST), and all other sarcomas including dermatofibrosarcoma protuberans, myxoid liposarcoma, perivascular endothelial cell sarcoma (PEComa), angiomyolipoma, and rhabdomyosarcoma. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST while striving toward improved therapeutic options. His work will involve the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.

Highlights

Selected Cancer-Related Publications

  • Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib,and nilotinib: A retrospective analysis. Eur J Cancer 49:1027-31,2013 Read more »
  • Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, Linassier C, Patel S, Benjamin RS, Trent JC. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med 2:553-63,2013 Read more »
  • Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R. BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 4:310-5,2013 Read more »
  • Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res 3:7,2013 Read more »
  • Wilky BA, Meyer CF, Trent JC. Pazopanib in sarcomas: expanding the PALETTE. Curr Opin Oncol 25:373-8,2013 Read more »
  • Yusuf SW, Bathina JD, Qureshi S, Kaynak HE, Banchs J, Trent JC, Ravi V, Daher IN, Swafford J. Cardiac tumors in a tertiary care cancer hospital: clinical features,echocardiographic findings,treatment and outcomes. Heart Int 7:e4,2012 Read more »
  • Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, Lòpez-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res 2:25,2012 Read more »
  • Dumont AG, Dumont SN, Trent JC. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer 31:327-334,2012 Read more »
  • Hatoum HT, Lin SJ, Sasane M, Trent JC. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based,matched-cohort study. Curr Med Res Opin 28:805-14,2012 Read more »
  • Dumont SN, Lazar AJ, Bridge JA, Benjamin RS, Trent JC. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. J Cancer Res Clin Oncol 138:213-20,2012 Read more »
  • Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin),a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther 11:2541-6,2012 Read more »
  • Yang JL, Cogdell D, Eddy J, Trent J, Price N, Zhang W. Expression of PRUNE2 mRNA and its positive correlation with non-coding RNA PCA3 in leiomyosarcoma]. Zhonghua Zhong Liu Za Zhi 34:497-500,2012 Read more »
  • Bustinza-Linares E, Socola F, Ernani V, Miller SA, Trent JC. Extraskeletal myxoid chondrosarcoma with small bowel metastasis causing bowel obstruction. Case Rep Oncol Med 2012:621025,2012 Read more »
  • Dumont AG, Yang Y, Reynoso D, Katz D, Trent JC, Hughes DP. Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. Carcinogenesis 33:1674-83,2012 Read more »

E-mail a Friend